Hoechst Aktiengesellschaft

Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Aventis Pharma Deutschland, Gmbh

Hoechst Aktiengellschaft

Max Hropot

Hans-Jochen Lang

Roman Muschaweck

Heinrich Christian Englert

Rainer Greger

Martin Bickel

Jochen Knolle

Klaus Wirth

Gerhard Breipohl

Ernold Granzer

Dieter Mania

Karl Sturm

Bela Kerekjarto

Joachim Brendel

Rolf Geiger

Uwe Heinelt

Hans Jochen Lang

Andreas W Herling

Wolfgang Konig

Armin Hofmeister

Uwe Gerlach

Holger Heitsch

Stephan Henke

Rainer Obermeier

Adalbert Wagner

Dominique Tripier

Markus Bleich

Jurgen Ludwig

Heinz G&ouml;gelein

Andreas Busch

Bernhard Seuring

Helmut Bohn

Henrich Christian Englert

Substituted cinnamic, acid guanidides, process for their preparation, their use as a medicament, and medicament comprising them

Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them

This invention relates to a method of treating a chronic fibrogenetic liver disorder and/or an acute liver disorder and/or complications associated therewith, comprising administering to a patient a therapeutically effective amount of a bradykinin antagonist. Particular complications associated with said liver disorders include portal hypertension, decompensation phenomena such as ascites, edema formation, hepatorenal syndrome, hypertensive gastropathy and colopathy, splenomegaly and hemorrhagic complications in the gastrointestinal tract due to portal hypertension, collateral circulation and hyperemia and a cardiopathy as a result of a chronically hyperdynamic circulatory situation and its consequences.

Use of bradykinin antagonists for the production of pharmaceuticals for

The invention relates to the use of nonpeptide bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders (hepatic cirrhosis and hepatic fibrosis), acute liver disorders and for the prevention of complications, in particular for the prophylaxis or treatment of portal hypertension, decompensation symptoms such as ascites, edema formation, hepatorenal syndrome, hypertensive gastropathy and colopathy, splenomegaly and hemorrhagic complications in the gastrointestinal tract due to portal hypertension, collateral circulation and hyperemia and a cardiopathy as a result of a chronically hyperdynamic circulatory situation and its consequences.

Use of nonpeptide bradykinin antagonists for the treatment and

Hirudin derivatives can be prepared by the selective enzymic replacement of a part of the molecule with an amino derivative. The hirudin derivatives are suitable for preparing pharmaceuticals having an anticoagulatory effect.

Hirudin derivatives and a process for their preparation

The invention relates to peptides of the formula

Peptides influencing diuresis and natriuresis, a process for their

Compounds I ##STR1## with R equal to hydrogen or (C.sub.1 -C.sub.4)-alkyl,

N-substituted 5-nitroanthranilic acids, a process for their preparation,

A description is given of a process for the preparation of a compound of the formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 (identical or different) represent H, alkyl having 1-2 carbon atoms and F, Cl, Br or I;

N-substituted aminoalkanoic acids, a process for their preparation,

Compounds of the formula I ##STR1## with R.sup.1 equal to H or (cyclo)alk(en)yl, R.sup.2 equal to H or alkyl, R.sup.3 equal to alkyl, R.sup.4 /R.sup.5 equal to H, alkyl or acyl, and Y equal to H, alkyl, CF.sub.3 or Hal, are described, as are processes for the preparation thereof. They are effective diuretics and antihypertensive agents with a lipid-lowering action.

Benzenesulfonamide derivatives and a process for the preparation thereof

A description is given of the use of amino-substituted benzoic acid derivatives of the formula I ##STR1## in which R.sup.1 and R.sup.2 denote hydrogen, (cyclo)alkyl, unsubstituted or substituted phenyl or naphthyl, or R.sup.1 and R.sup.2 together denote a chain --(CH.sub.2).sub.m -- with m=3 to 6, or together denote a chain --(CH.dbd.CH).sub.n -- with n equal to 2 or 3; R.sup.3 denotes hydrogen, halogen or alkyl; R.sup.4 denotes hydrogen or NO.sub.2 ; R.sup.5 denotes hydrogen or a radical which can be eliminated under physiological conditions; for the preparation of a remedy for diarrhea.

Use of amino-substituted benzoic acids as remedies for diarrhea, and

Benzenesulfonamide derivatives and a process for the medical use thereof

The invention relates to 2-aminomethylphenols of the formula I ##STR1## in which R.sup.1 and R.sup.2 represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or benzyl which is optionally substituted by alkyl, alkoxy or halogen, R.sup.3 and R.sup.5 denote hydrogen, halogen, alkyl or alkoxy, R.sup.4 denotes halogen, alkyl or cycloalkyl and R.sup.6 and R.sup.7 represent hydrogen or alkyl, it being possible for the radicals R.sup.1 and R.sup.2, R.sup.6 R.sup.7 and/or two of the radicals R.sup.3, R.sup.4 and R.sup.5 to form an alkylene chain which is optionally substituted by methyl groups and which, in the case of the radicals R.sup.1, R.sup.2, R.sup.6 and R.sup.7, can also be interrupted by oxygen atoms, sulfur atoms and/or imino groups, and to physiologically acceptable salts thereof, a process for their preparation, and their use and to pharmaceutical formulations based on these compounds.

2-Aminomethyl-6-sulfamoylphenol derivatives with salidiuretic activities

The invention relates to 2-aminomethylphenols of the formula I ##STR1## in which R.sup.1 and R.sup.2 represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or benzyl which is optionally substituted by alkyl, alkoxy or halogen, R.sup.3 and R.sup.5 denote hydrogen, halogen, alkyl or alkoxy, R.sup.4 denotes halogen, alkyl or cycloalkyl and R.sup.6 and R.sup.7 represents hydrogen or alkyl, it being possible for the radicals R.sup.1 and R.sup.2, R.sup.6 and R.sup.7 and/or two of the radicals R.sup.3, R.sup.4 and R.sup.5 to form an alkylene chain which is optionally substituted by methyl groups and which, in the case of the radicals R.sup.1, R.sup.2, R.sup.6 and R.sup.7, can also be interrupted by oxygen atoms, sulfur atoms and/or imino groups, and to physiologically acceptable salts thereof, a process for their preparation, and their use and to pharmaceutical formulations based on these compounds.

2-aminomethyl-6-sulfamoylphenol derivatives, a process for their

5-(4-Chloro-3-sulfamoylbenzoyl)-2,3-dihydro-2-benzofurancarboxylic acids of the formula I ##STR1## in which R.sup.1 and R.sup.2 are identical or different and represent hydrogen, halogen or methyl, both as racemic mixtures and in the form of their optical isomers, and their physiologically tolerated salts are described, as is their preparation. They are outstanding diuretics and saluretics with an additional uricosuric component.

5-(4-Chloro-3-sulfamoylbenzoyl)-2,3-dihydro-2-benzofurancarboxylic acids

What are disclosed are salidiuretic compounds of the formula ##STR1## and physiologically acceptable salts thereof, wherein R is phenyl, furyl or thienyl, intermediates of said compounds, methods for making said compounds, salidiuretic pharmaceutical preparations containing said compounds or salts, and methods for treating humans and other mammals with such compounds or salts.

5-Phenyltetrazoles and their use as salidiuretics

Growing community of inventors

Florsheim am Main, Germany

Max Hropot